+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Paraneoplastic syndromes in patients with hepatocellular carcinoma in Taiwan



Paraneoplastic syndromes in patients with hepatocellular carcinoma in Taiwan



Cancer 86(5): 799-804



BACKGROUND. Hepatocellular carcinoma (HCC) is the most common malignancy in Taiwan. Some patients may manifest paraneoplastic syndromes during the clinical course of the disease. In this study, the authors evaluated the clinical significance of these paraneoplastic syndromes, compared the prevalence of these syndromes between cases of hepatitis B virus (HBV)-related and hepatitis C virus (HCV)-related HCC, and estimated significant predictors associated with the syndromes. METHODS. Clinical data on 1197 HCC patients, including age, gender, Child-Pugh score, survival time, laboratory data (including liver biochemistry, hepatitis markers, and serum alpha-fetoprotein (AFP)), and tumor features (including tumor size, portal vein thrombosis, and histologic pictures), were retrospectively reviewed. RESULTS. A total of 232 of 1197 patients (19.4%) had paraneoplastic syndromes. HCC patients with paraneoplastic syndromes had significantly higher serum AFP; higher rates of initial main portal vein thrombosis, metastasis, and bilobal tumor involvement; larger tumor volume; and shorter survival than those without these syndromes. Patients with HBV-related HCC had a significantly higher prevalence of paraneoplastic syndromes than patients with HCV-related HCC (20.1% vs. 11.2%, P = 0.005). In a stepwise multivariate logistic regression analysis, AFP >50,000 ng/mL and tumor volume >30% were significant predictive variables associated with the presence of paraneoplastic syndromes in HCC patients. CONCLUSIONS. HCC patients with paraneoplastic syndromes usually had higher levels of serum AFP and larger tumor volumes than those without. Patients with HBV-related HCC had a significantly higher prevalence of paraneoplastic syndromes than those with HCV-related HCC.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011116341

Download citation: RISBibTeXText

PMID: 10463978

DOI: 10.1002/(sici)1097-0142(19990901)86:5<799::aid-cncr15>3.0.co;2-#


Related references

The incidence and characteristics of some paraneoplastic syndromes of hepatocellular carcinoma in Nigerian patients. European Journal of Gastroenterology and Hepatology 11(12): 1401-1404, 1999

Clinical characteristics and prognosis of hepatocellular carcinoma patients with paraneoplastic syndromes. Hepato-Gastroenterology 49(47): 1315-1319, 2002

The incidence and clinical significance of paraneoplastic syndromes in patients with hepatocellular carcinoma. Korean Journal of Hepatology 11(3): 275-283, 2005

Epidemiology and prognosis of paraneoplastic syndromes in hepatocellular carcinoma. Isrn Oncology 2013: 684026, 2013

Prognostic role and significance of paraneoplastic syndromes in hepatocellular carcinoma. American Surgeon 80(2): 191-196, 2014

Paraneoplastic syndromes in three patients with renal cell carcinoma. Nederlands Tijdschrift Voor Geneeskunde 148(10): 487-492, 2004

Hypercholinesterasemia in patients with hepatocellular carcinoma: a new paraneoplastic syndrome. Gastroenterologia Japonica 18(2): 137-141, 1983

Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma. World Journal of Gastroenterology 10(17): 2472-2477, 2004

Paraneoplastic syndromes are associated with adverse prognosis among patients with renal cell carcinoma undergoing nephrectomy. World Journal of Urology 34(10): 1465-1472, 2016

Paraneoplastic syndromes (PNS) associated with Merkel cell carcinoma (MCC): A case series of 8 patients highlighting different clinical manifestations. Journal of the American Academy of Dermatology 75(3): 541-547, 2016

Incidence of paraneoplastic syndromes in a series of 204 hepatocellular carcinomas. Acta Gastro-Enterologica Belgica 48(4): 352-369, 1985

Recombinant immunoblot for assessment of intrathecally synthesised paraneoplastic antineuronal antibodies in cerebrospinal fluid from patients with paraneoplastic neurological syndromes. Clinical Chemistry and Laboratory Medicine 46(12): 1793-1795, 2008

The distribution of HLA-A, B, C, DR antigens in Chinese patients with hepatocellular carcinoma in Taiwan. Tissue Antigens 29(2): 110-114, 1987

Hospice palliative care for patients with hepatocellular carcinoma in Taiwan. Palliative Medicine 18(2): 93-99, 2004